KQB548 for advanced solid tumors with KRAS G12D mutation
Part of Cancer clinical trials.
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: pancreatic, colorectal, or non-small cell lung cancer, with a KRAS G12D mutation
- Your cancer has spread or cannot be removed with surgery, and you've already tried at least one standard treatment that didn't work or caused side effects you couldn't handle
- Your tumors can be measured on scans (like CT or MRI)
- Your liver, kidneys, and other organs are working well enough
- You have not taken any drug that targets KRAS G12D or all forms of RAS before
- You don't have serious stomach or bowel problems, and you can swallow pills
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
This trial tests a new oral drug (KQB168) given alone or with other medicines for people with advanced solid tumors that have not responded to immunotherapy. The goal is to see if it is safe and can help shrink or slow the growth of cancer.
This trial tests a new drug called QTX3034 in people whose cancer has a specific genetic change called KRAS G12D. The drug aims to block the mutated protein that helps cancer grow, and may work even if other treatments have stopped working.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.